AgomAb Therapeutics NV, a company focused on developing innovative biological products, has reported a notable stock transaction involving one of its directors. David R. Epstein acquired 10,000 shares of the company's common stock on October 21, 2026. This transaction is significant as it demonstrates Epstein's confidence in AgomAb's growth potential and future prospects.
According to the recent SEC filing, Epstein's purchase included two separate transactions of 5,000 shares each, priced at $8.86 and $8.90 per share. Following these transactions, Epstein now owns a total of 25,000 shares in AgomAb, reflecting his direct ownership in the company.
Background
AgomAb Therapeutics NV operates in the biological products sector, specifically classified under SIC code 2836, which pertains to biological products (no diagnostic substances). The company is listed on the Nasdaq under the ticker symbol AGMB. AgomAb is categorized as a non-accelerated filer and an emerging growth company, indicating its focus on innovative solutions in the life sciences field.
What the Filing Says
The filing, with accession number 0001445826-26-000015, details Epstein's acquisition of shares, stating, "transaction code P" for the purchases made on October 21. This transaction reflects a direct ownership nature, further solidifying Epstein's stake in the company.
Impact
This acquisition may affect the perception of AgomAb among investors and analysts, as insider purchases often signal confidence in a company's future performance. Epstein's increased stake could also attract attention from potential investors looking for signs of stability and growth within the biological products industry.
What's Next
The filing does not say what happens next.